Bayvrio has added an unbranded biosimilar to Humira® (adalimumab) to the Bayvrio Marketplace, available to any hospital or licensed specialty pharmacy in the U.S. Priced at 95% below the reference drug’s wholesale acquisition cost, the unbranded Adalimumab-ryvk represents the next milestone in Bayvrio’s mission to dismantle legacy supply chain barriers and restore financial control to payers.
A new standard for affordability
Specialty spend, driven largely by high-cost biologics like Humira, has long been a significant pain point for health systems and PBMs. By offering an unbranded version at a fraction of the cost, Bayvrio is bypassing the complex and opaque models that keep lower-cost options out of reach for patients and plan sponsors.
Manufactured by Anda, an affiliate of Teva Pharmaceuticals USA, Inc., Adalimumab-ryvk is the second biosimilar integrated into the Marketplace in just six months. It will be available for purchase starting July 1, 2026, through Birdi Wholesale, a trusted supplier within the Bayvrio ecosystem.
Breaking the legacy model
“This launch is about more than just a new product; it is an entirely new approach to the drug supply chain,” said Mike Napolitano, President of Bayvrio. “Legacy supply models have limited access to biosimilars and kept prices artificially high. We are upending that model to drive prices lower and put control back into the hands of payers and pharmacies.”
Flexibility through modularity
The Bayvrio Marketplace is designed to move away from the “all-or-nothing” approach of traditional PBMs. It gives healthcare payers a new way forward – a curated, modular ecosystem of pharmacy solutions so they can build a pharmacy strategy that delivers control, transparency, and flexibility without the cost, risk, or disruption of building it alone.
Payers can seamlessly integrate their own capabilities and third-party partners and combine them with Bayvrio’s best-in-class solutions, including:
- Integrated cash and specialty strategies that expand member access to lower-cost alternatives while preserving benefit alignment.
- Formularies and clinical programs powered by real-time insights to drive adherence, appropriate utilization, and measurable outcomes.
- Optimized network strategies that expand access, strengthen performance, and help ensure members receive medications through the most effective channel.
This modular structure empowers payers to optimize pharmacy revenue streams, drive cost savings, improve outcomes, and simplify the member experience.